Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2018, Article ID 8023821, 18 pages
https://doi.org/10.1155/2018/8023821
Review Article

Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy

1School of Medicine, University of Split, Šoltanska 2, 21000 Split, Croatia
2Faculty of Science, University of Split, Ruđera Boškovića 33, 21000 Split, Croatia

Correspondence should be addressed to Ivana Novak; rh.tsfem@kavon.anavi

Received 28 July 2017; Revised 13 November 2017; Accepted 14 December 2017; Published 31 January 2018

Academic Editor: Nikolai Engedal

Copyright © 2018 Mija Marinković et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Z. Yang and D. J. Klionsky, “Eaten alive: a history of macroautophagy,” Nature Cell Biology, vol. 12, no. 9, pp. 814–822, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Mizushima and M. Komatsu, “Autophagy: renovation of cells and tissues,” Cell, vol. 147, no. 4, pp. 728–741, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Arakawa, S. Honda, H. Yamaguchu, and S. Shimizu, “Molecular mechanisms and physiological roles of Atg5/Atg7-independent alternative autophagy,” Proceedings of the Japan Academy, Series B, vol. 93, no. 6, pp. 378–385, 2017. View at Publisher · View at Google Scholar
  4. N. Mizushima and B. Levine, “Autophagy in mammalian development and differentiation,” Nature Cell Biology, vol. 12, no. 9, pp. 823–830, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Tsukada and Y. Ohsumi, “Isolation and characterization of autophagy-defective mutants of Saccharomyces cerevisiae,” FEBS Letters, vol. 333, no. 1-2, pp. 169–174, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Mizushima, Y. Ohsumi, and T. Yoshimori, “Autophagosome formation in mammalian cells,” Cell Structure and Function, vol. 27, no. 6, pp. 421–429, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. W. W. Li, J. Li, and J. K. Bao, “Microautophagy: lesser-known self-eating,” Cellular and Molecular Life Sciences, vol. 69, no. 7, pp. 1125–1136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. M. Cuervo and E. Wong, “Chaperone-mediated autophagy: roles in disease and aging,” Cell Research, vol. 24, no. 1, pp. 92–104, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Xie and D. J. Klionsky, “Autophagosome formation: core machinery and adaptations,” Nature Cell Biology, vol. 9, no. 10, pp. 1102–1109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Nishida, S. Arakawa, K. Fujitani et al., “Discovery of Atg5/Atg7-independent alternative macroautophagy,” Nature, vol. 461, no. 7264, pp. 654–658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. P. M. Wong, C. Puente, I. G. Ganley, and X. Jiang, “The ULK1 complex sensing nutrient signals for autophagy activation,” Autophagy, vol. 9, no. 2, pp. 124–137, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Y. Chan, “mTORC1 phosphorylates the ULK1-mAtg13-FIP200 autophagy regulatory complex,” Science Signaling, vol. 2, no. 84, pp. 1–3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Torii, T. Yoshida, S. Arakawa, S. Honda, and A. Nakanishi, “Identification of PPM1D as an essential Ulk 1 phosphatase for genotoxic stress-induced autophagy,” EMBO Reports, vol. 17, no. 11, pp. 1552–1564, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Itakura, C. Kishi, K. Inoue, and N. Mizushima, “Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG,” Molecular Biology of the Cell, vol. 19, no. 12, pp. 5360–5372, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Geng and D. J. Klionsky, “The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. ‘Protein modifications: beyond the usual suspects’ review series,” EMBO Reports, vol. 9, no. 9, pp. 859–864, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Suzuki, Y. Kubota, T. Sekito, and Y. Ohsumi, “Hierarchy of Atg proteins in pre-autophagosomal structure organization,” Genes to Cells, vol. 12, no. 2, pp. 209–218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Kabeya, “LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing,” The EMBO Journal, vol. 19, no. 21, pp. 5720–5728, 2000. View at Publisher · View at Google Scholar
  18. C. M. Kenific and J. Debnath, “Cellular and metabolic functions for autophagy in cancer cells,” Trends in Cell Biology, vol. 25, no. 1, pp. 37–45, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Mizushima, T. Yoshimori, and B. Levine, “Methods in mammalian autophagy research,” Cell, vol. 140, no. 3, pp. 313–326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Barth, D. Glick, and K. F. Macleod, “Autophagy: assays and artifacts,” The Journal of Pathology, vol. 221, no. 2, pp. 117–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Ichimura, T. Kirisako, T. Takao et al., “A ubiquitin-like system mediates protein lipidation,” Nature, vol. 408, no. 6811, pp. 488–492, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Kabeya, N. Mizushima, A. Yamamoto, S. Oshitani-Okamoto, Y. Ohsumi, and T. Yoshimori, “LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation,” Journal of Cell Science, vol. 117, no. 13, pp. 2805–2812, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. D. J. Klionsky, K. Abdelmohsen, A. Abe et al., “Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition),” Autophagy, vol. 12, no. 1, pp. 1–222, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. M. G. Gutierrez, D. B. Munafo, W. Beron, and M. I. Colombo, “Rab7 is required for the normal progression of the autophagic pathway in mammalian cells,” Journal of Cell Science, vol. 117, no. 13, pp. 2687–2697, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Jager, C. Bucci, I. Tanida et al., “Role for Rab7 in maturation of late autophagic vacuoles,” Journal of Cell Science, vol. 117, no. 20, pp. 4837–4848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Jiang, T. Nishimura, Y. Sakamaki et al., “The HOPS complex mediates autophagosome–lysosome fusion through interaction with syntaxin 17,” Molecular Biology of the Cell, vol. 25, no. 8, pp. 1327–1337, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Itakura, C. Kishi-Itakura, and N. Mizushima, “The hairpin-type tail-anchored SNARE syntaxin 17 targets to autophagosomes for fusion with endosomes/lysosomes,” Cell, vol. 151, no. 6, pp. 1256–1269, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Diao, R. Liu, Y. Rong et al., “ATG14 promotes membrane tethering and fusion of autophagosomes to endolysosomes,” Nature, vol. 520, no. 7548, pp. 563–566, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Kuma, M. Hatano, M. Matsui et al., “The role of autophagy during the early neonatal starvation period,” Nature, vol. 432, no. 7020, pp. 1032–1036, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Komatsu, S. Waguri, T. Ueno et al., “Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice,” The Journal of Cell Biology, vol. 169, no. 3, pp. 425–434, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Lombardi, T. Soldati, M. A. Riederer, Y. Goda, M. Zerial, and S. R. Pfeffer, “Rab9 functions in transport between late endosomes and the trans Golgi network,” The EMBO Journal, vol. 12, pp. 677–682, 1993. View at Google Scholar
  32. M. A. Riederer, T. Soldati, A. D. Shapiro, J. Lin, and S. R. Pfeffer, “Lysosome biogenesis requires Rab9 function and receptor recycling from endosomes to the trans-Golgi network,” The Journal of Cell Biology, vol. 125, pp. 573–582, 1994. View at Publisher · View at Google Scholar
  33. M. Hayashi-Nishino, N. Fujita, T. Noda, A. Yamaguchi, T. Yoshimori, and A. Yamamoto, “A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation,” Nature Cell Biology, vol. 11, no. 12, pp. 1433–1437, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. S. A. Tooze and T. Yoshimori, “The origin of the autophagosomal membrane,” Nature Cell Biology, vol. 12, no. 9, pp. 831–835, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Beau, M. Mehrpour, and P. Codogno, “Autophagosomes and human diseases,” The International Journal of Biochemistry & Cell Biology, vol. 43, no. 4, pp. 460–464, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. V. E. Kwitkowski, T. M. Prowell, A. Ibrahim et al., “FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma,” Oncologia, vol. 15, no. 4, pp. 428–435, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Anandappa, A. Hollingdale, and T. Eisen, “Everolimus – a new approach in the treatment of renal cell carcinoma,” Cancer Management and Research, vol. 2, pp. 61–70, 2010. View at Google Scholar
  38. J. C. Yao, M. H. Shah, T. Ito et al., “Everolimus for advanced pancreatic neuroendocrine tumors,” The New England Journal of Medicine, vol. 364, no. 6, pp. 514–523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Dhillon, “Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer,” Drugs, vol. 73, no. 5, pp. 475–485, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Kirschey, S. Wagner, and G. Hess, “Relapsed and/or refractory mantle cell lymphoma: what role for temsirolimus?” Clinical Medicine Insights: Oncology, vol. 6, pp. 153–164, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Galluzzi, “Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles,” Nature Reviews Drug Discovery, vol. 16, no. 7, pp. 487–511, 2017. View at Publisher · View at Google Scholar
  42. Y.-P. Yang, L. F. Hu, H. F. Zheng et al., “Application and interpretation of current autophagy inhibitors and activators,” Acta Pharmacologica Sinica, vol. 34, no. 5, pp. 625–635, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. J.-L. Bian, M. M. Wang, E. J. Tong et al., “Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with PIK3CA mutation,” World Journal of Gastroenterology, vol. 23, no. 23, pp. 4311–4316, 2017. View at Publisher · View at Google Scholar
  44. R. Kumar and A. Kapoor, “Current management of metastatic renal cell carcinoma: evolving new therapies,” Current Opinion in Supportive and Palliative Care, vol. 11, no. 3, pp. 231–237, 2017. View at Publisher · View at Google Scholar
  45. C. Seliger, C. R. Meier, C. Becker et al., “Diabetes, use of metformin, and the risk of meningioma,” PLoS One, vol. 12, no. 7, p. e0181089, 2017. View at Publisher · View at Google Scholar
  46. P. M. Njaria, J. Okombo, N. M. Njuguna, and K. Chibale, “Chloroquine-containing compounds: a patent review (2010 – 2014),” Expert Opinion on Therapeutic Patents, vol. 25, no. 9, pp. 1003–1024, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Renna, C. Schaffner, K. Brown et al., “Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobaterial infection,” The Journal of Clinical Investigation, vol. 121, no. 9, pp. 3554–3563, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Villanueva Paz, D. Cotán, J. Garrido-Maraver et al., “Targeting autophagy and mitophagy for mitochondrial diseases treatment,” Expert Opinion on Therapeutic Targets, vol. 20, no. 4, pp. 487–500, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. Z. Luo, A. K. Saha, X. Xiang, and N. B. Ruderman, “AMPK, the metabolic syndrome and cancer,” Trends in Pharmacological Sciences, vol. 26, no. 2, pp. 69–76, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. D. F. Egan, D. B. Shackelford, M. M. Mihaylova et al., “Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy,” Science, vol. 331, no. 6016, pp. 456–461, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. D. M. Gwinn, D. B. Shackelford, D. F. Egan et al., “AMPK phosophorylation of raptor mediates a metabolic checkpoint,” Molecular Cell, vol. 30, no. 2, pp. 214–226, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. S. S. Jäger, C. C. Handschin, J. J. St-Pierre, and B. M. Spiegelman, “AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 29, pp. 12017–12022, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. G. D. Hardie, F. A. Ross, and S. A. Hawley, “AMPK: a nutrient and energy sensor that maintains energy homeostasis,” Nature Reviews. Molecular Cell Biology, vol. 13, no. 4, pp. 251–262, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Kim, M. Kundu, B. Viollet, and K.-L. Guan, “AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1,” Nature Cell Biology, vol. 13, no. 2, pp. 132–141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Hay and N. Sonenberg, “Upstream and downstream of mTOR,” Genes & Development, vol. 18, no. 16, pp. 1926–1945, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. M. E. Feldman, B. Apsel, A. Uotila et al., “Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2,” PLoS Biology, vol. 7, no. 2, p. e1000038, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Jacinto, R. Loewith, A. Schmidt et al., “Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive,” Nature Cell Biology, vol. 6, no. 11, pp. 1122–1128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Kaur and S. Sharma, “Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases,” Inflammopharmacology, vol. 25, no. 3, pp. 293–312, 2017. View at Publisher · View at Google Scholar · View at Scopus
  59. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA: a Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017. View at Publisher · View at Google Scholar · View at Scopus
  60. N. Mizushima, T. Yoshimori, and Y. Ohsumi, “The role of Atg proteins in autophagosome formation,” Annual Review of Cell and Developmental Biology, vol. 27, no. 1, pp. 107–132, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Levine and D. J. Klionsky, “Development by self-digestion: molecular mechanisms and biological functions of autophagy,” Developmental Cell, vol. 6, no. 4, pp. 463–477, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. K. H. Kim and M.-S. Lee, “Autophagy–a key player in cellular and body metabolism,” Nature Reviews Endocrinology, vol. 10, no. 6, pp. 322–337, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. B. Levine, N. Mizushima, and H. W. Virgin, “Autophagy in immunity and inflammation,” Nature, vol. 469, no. 7330, pp. 323–335, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. D. C. Rubinsztein, G. Mariño, and G. Kroemer, “Autophagy and aging,” Cell, vol. 146, no. 5, pp. 682–695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. P. E. Schwarze and P. O. Seglen, “Reduced autophagic activity, improved protein balance and enhanced in vitro survival of hepatocytes isolated from carcinogen-treated rats,” Experimental Cell Research, vol. 157, no. 1, pp. 15–28, 1985. View at Publisher · View at Google Scholar · View at Scopus
  66. Z. J. Yang, C. E. Chee, S. Huang, and F. A. Sinicrope, “The role of autophagy in cancer: therapeutic implications,” Molecular Cancer Therapeutics, vol. 10, no. 9, pp. 1533–1541, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Shintani, “Autophagy in health and disease: a double-edged sword,” Science, vol. 306, no. 5698, pp. 990–995, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. B. Levine and J. Yuan, “Autophagy in cell death: an innocent convict?” The Journal of Clinical Investigation, vol. 115, no. 10, pp. 2679–2688, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. B. Levine and G. Kroemer, “Autophagy in the pathogenesis of disease,” Cell, vol. 132, no. 1, pp. 27–42, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. P. A. Futreal, P. Söderkvist, J. R. Marks et al., “Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms,” Cancer Research, vol. 52, pp. 2624–2627, 1992. View at Google Scholar
  71. X. Gao, A. Zacharek, A. Salkowski et al., “Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer,” Cancer Research, vol. 55, no. 5, pp. 1002–1005, 1995. View at Google Scholar
  72. V. M. Aita, X. H. Liang, V. V. V. S. Murty et al., “Cloning and genomic organization of Beclin 1, a candidate tumor suppressor gene on chromosome 17q21,” Genomics, vol. 59, no. 1, pp. 59–65, 1999. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Cai, Z. Hu, J. Liu et al., “Beclin 1 expression in ovarian tissues and its effects on ovarian cancer prognosis,” International Journal of Molecular Sciences, vol. 15, no. 4, pp. 5292–5303, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. D.-M. Qiu, G. L. Wang, L. Chen et al., “The expression of beclin-1, an autophagic gene, in hepatocellular carcinoma associated with clinical pathological and prognostic significance,” BMC Cancer, vol. 14, no. 1, p. 327, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. Z. Zhang, Z. Shao, L. Xiong, B. Che, C. Deng, and W. Xu, “Expression of Beclin1 in osteosarcoma and the effects of down-regulation of autophagy on the chemotherapeutic sensitivity,” Journal of Huazhong University of Science Technology [Medical Science], vol. 29, pp. 737–740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. X. Huang, H. M. Bai, L. Chen, B. Li, and Y. C. Lu, “Reduced expression of LC3B-II and Beclin 1 in glioblastoma multiforme indicates a down-regulated autophagic capacity that relates to the progression of astrocytic tumors,” Journal of Clinical Neuroscience, vol. 17, no. 12, pp. 1515–1519, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Li, N. Hou, A. Faried, S. Tsutsumi, and H. Kuwano, “Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model,” European Journal of Cancer, vol. 46, no. 10, pp. 1900–1909, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. G. Nicotra, F. Mercalli, C. Peracchio et al., “Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomas,” Modern Pathology, vol. 23, no. 7, pp. 937–950, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. Y. Ionov, N. Nowak, M. Perucho, S. Markowitz, and J. K. Cowell, “Manipulation of nonsense mediated decay identifies gene mutations in colon cancer cells with microsatellite instability,” Oncogene, vol. 23, no. 3, pp. 639–645, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. M. S. Kim, E. G. Jeong, C. H. Ahn, S. S. Kim, S. H. Lee, and N. J. Yoo, “Frameshift mutation of UVRAG, an autophagy-related gene, in gastric carcinomas with microsatellite instability,” Human Pathology, vol. 39, no. 7, pp. 1059–1063, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. Takahashi, D. Coppola, N. Matsushita et al., “Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis,” Nature Cell Biology, vol. 9, no. 10, pp. 1142–1151, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Tang, A. Ahmad, and F. H. Sarkar, “The role of microRNAs in breast cancer migration, invasion and metastasis,” International Journal of Molecular Sciences, vol. 13, no. 12, pp. 13414–13437, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Jiang, Y. Li, Y. H. Zhu et al., “Intensive expression of UNC-51-like kinase 1 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma,” Cancer Science, vol. 102, no. 8, pp. 1568–1575, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Xu, H. Yu, X. Zhang et al., “UNC51-like kinase 1 as a potential prognostic biomarker for hepatocellular carcinoma,” International Journal of Clinical and Experimental Pathology, vol. 6, pp. 711–717, 2013. View at Google Scholar
  85. M. Yun, H. Y. Bai, J. X. Zhang et al., “ULK1: a promising biomarker in predicting poor prognosis and therapeutic response in human nasopharygeal carcinoma,” PLoS One, vol. 10, no. 2, pp. e0117375–e0117315, 2015. View at Publisher · View at Google Scholar · View at Scopus
  86. M.-B. Chen, X. Z. Ji, Y. Y. Liu et al., “Ulk1 over-expression in human gastric cancer is correlated with patients’ T classification and cancer relapse,” Oncotarget, vol. 8, no. 20, pp. 33704–33712, 2017. View at Publisher · View at Google Scholar · View at Scopus
  87. K. Degenhardt, R. Mathew, B. Beaudoin et al., “Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis,” Cancer Cell, vol. 10, no. 1, pp. 51–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Yang, X. Wang, G. Contino et al., “Pancreatic cancers require autophagy for tumor growth,” Genes & Development, vol. 25, no. 7, pp. 717–729, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. H. Wei, S. Wei, B. Gan, X. Peng, W. Zou, and J. L. Guan, “Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis,” Genes & Development, vol. 25, no. 14, pp. 1510–1527, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. J. Ge, Z. Chen, J. Huang et al., “Upregulation of autophagy-related Gene-5 (ATG-5) is associated with chemoresistance in human gastric cancer,” PLoS One, vol. 9, no. 10, p. e110293, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. M. S. Kim, S. Y. Song, J. Y. Lee, N. J. Yoo, and S. H. Lee, “Expressional and mutational analyses of ATG5 gene in prostate cancers,” APMIS, vol. 119, no. 11, pp. 802–807, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. J. Zhu, Y. Li, Z. Tian et al., “ATG7 overexpression is crucial for tumorigenic growth of bladder cancer in vitro and in vivo by targeting the ETS2/miRNA196b/FOXO1/p27 axis,” Molecular Therapy - Nucleic Acids, vol. 7, pp. 299–313, 2017. View at Publisher · View at Google Scholar
  93. A. Takamura, M. Komatsu, T. Hara et al., “Autophagy-deficient mice develop multiple liver tumors,” Genes & Development, vol. 25, no. 8, pp. 795–800, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. C. J. Bakkenist and M. B. Kastan, “DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation,” Nature, vol. 421, no. 6922, pp. 499–506, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. P. Boya, R. A. Gonzalez-Polo, D. Poncet et al., “Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine,” Oncogene, vol. 22, no. 25, pp. 3927–3936, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. P. D. Jiang, Y. L. Zhao, X. Q. Deng et al., “Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer,” Biomedicine & Pharmacotherapy, vol. 64, no. 9, pp. 609–614, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Michaud, I. Martins, A. Q. Sukkurwala et al., “Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice,” Science, vol. 334, no. 6062, pp. 1573–1577, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Vincent, J. Herman, R. Schulick, R. H. Hruban, and M. Goggins, “Pancreatic cancer,” Lancet, vol. 378, no. 9791, pp. 607–620, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. D. P. Ryan, T. S. Hong, and N. Bardeesy, “Pancreatic Adenocarcinoma,” The New England Journal of Medicine, vol. 371, no. 11, pp. 1039–1049, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. C. Almoguera, D. Shibata, K. Forrester, J. Martin, N. Arnheim, and M. Perucho, “Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes,” Cell, vol. 53, no. 4, pp. 549–554, 1988. View at Publisher · View at Google Scholar · View at Scopus
  101. A. J. Aguirre, N. Bardeesy, M. Sinha et al., “Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma,” Genes & Development, vol. 17, no. 24, pp. 3112–3126, 2003. View at Publisher · View at Google Scholar · View at Scopus
  102. S. R. Hingorani, E. F. Petricoin III, A. Maitra et al., “Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse,” Cancer Cell, vol. 4, no. 6, pp. 437–450, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. J. M. Nigro, S. J. Baker, A. C. Preisinger et al., “Mutations in the p53 gene occur in diverse human tumour types,” Nature, vol. 342, no. 6250, pp. 705–708, 1989. View at Publisher · View at Google Scholar
  104. A. Yang, N. V. Rajeshkumar, X. Wang et al., “Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations,” Cancer Discovery, vol. 4, no. 8, pp. 905–913, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. M. T. Rosenfeldt, J. O’Prey, J. P. Morton et al., “p53 status determines the role of autophagy in pancreatic tumour development,” Nature, vol. 504, no. 7479, pp. 296–300, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. B. M. Wolpin, D. A. Rubinson, X. Wang et al., “Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma,” The Oncologist, vol. 19, no. 6, pp. 637-638, 2014. View at Publisher · View at Google Scholar · View at Scopus
  107. X. H. Liang, S. Jackson, M. Seaman et al., “Induction of autophagy and inhibition of tumorigenesis by beclin 1,” Nature, vol. 402, no. 6762, pp. 672–676, 1999. View at Publisher · View at Google Scholar · View at Scopus
  108. X. Qu, J. Yu, G. Bhagat et al., “Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene,” The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1809–1820, 2003. View at Publisher · View at Google Scholar
  109. Z. Yue, S. Jin, C. Yang, A. J. Levine, and N. Heintz, “Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 15077–15082, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. S. Pankiv, T. H. Clausen, T. Lamark et al., “p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy,” The Journal of Biological Chemistry, vol. 282, no. 33, pp. 24131–24145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. G. Bjørkøy, T. Lamark, A. Brech et al., “p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death,” The Journal of Cell Biology, vol. 171, no. 4, pp. 603–614, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. J. Moscat and M. T. Diaz-Meco, “p62 at the crossroads of autophagy, apoptosis, and cancer,” Cell, vol. 137, no. 6, pp. 1001–1004, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. D. C. Rubinsztein, P. Codogno, and B. Levine, “Autophagy modulation as a potential therapeutic target for diverse diseases,” Nature Reviews. Drug Discovery, vol. 11, no. 9, pp. 709–730, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. E. White and W. Edu, “Deconvoluting the context-dependent role for autophagy in cancer,” Nature Reviews Cancer, vol. 12, no. 6, pp. 401–410, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. A. Duran, J. F. Linares, A. S. Galvez et al., “The signaling adaptor p62 is an important NF-κB mediator in tumorigenesis,” Cancer Cell, vol. 13, no. 4, pp. 343–354, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. J. Y. Guo, H. Y. Chen, R. Mathew et al., “Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis,” Genes & Development, vol. 25, no. 5, pp. 460–470, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. R. Mathew, C. M. Karp, B. Beaudoin et al., “Autophagy suppresses tumorigenesis through elimination of p62,” Cell, vol. 137, no. 6, pp. 1062–1075, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. H. Wei, C. Wang, C. M. Croce, and J. L. Guan, “p62/SQSTM1 synergizes with autophagy for tumor growth in vivo,” Genes & Development, vol. 28, no. 11, pp. 1204–1216, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. T. Negri, E. Tarantino, M. Orsenigo et al., “Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification,” Genes, Chromosomes and Cancer, vol. 49, no. 10, pp. 901–909, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. C. M. Perou, T. Sørlie, M. B. Eisen et al., “Molecular portraits of human breast tumours,” Nature, vol. 406, no. 6797, pp. 747–752, 2000. View at Publisher · View at Google Scholar · View at Scopus
  121. F. Lozy, X. Cai-McRae, I. Teplova et al., “ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss,” Autophagy, vol. 10, no. 4, pp. 662–676, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. Y. Huo, H. Cai, I. Teplova et al., “Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer,” Cancer Discovery, vol. 3, no. 8, pp. 894–907, 2013. View at Publisher · View at Google Scholar · View at Scopus
  123. K. Sun, X. L. Guo, Q. D. Zhao et al., “Paradoxical role of autophagy in the dysplastic and tumor-forming stages of hepatocarcinoma development in rats,” Cell Death & Disease, vol. 4, no. 2, pp. e501–e511, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. C. L. Chen, Y. W. Tseng, J. C. Wu et al., “Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and microRNA regulation,” Biomaterials, vol. 44, pp. 71–81, 2015. View at Publisher · View at Google Scholar · View at Scopus
  125. D. H. Wu, C. C. Jia, J. Chen et al., “Autophagic LC3B overexpression correlates with malignant progression and predicts a poor prognosis in hepatocellular carcinoma,” Tumor Biology, vol. 35, no. 12, pp. 12225–12233, 2014. View at Publisher · View at Google Scholar · View at Scopus
  126. Y. Tian, C.f. Kuo, D. Sir et al., “Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis,” Cell Death and Differentiation, vol. 22, no. 6, pp. 1025–1034, 2015. View at Publisher · View at Google Scholar · View at Scopus
  127. G. Ø. Kisen, L. Tessitore, P. Costelli et al., “Reduced autophagic activity in primary rat hepatocellular carcinoma and ascites hepatoma cells,” Carcinogenesis, vol. 14, no. 12, pp. 2501–2505, 1993. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Huang and P. J. Houghton, “Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic,” Current Opinion in Investigational Drugs, vol. 3, no. 2, pp. 295–304, 2002. View at Google Scholar
  129. C. Toso, S. Merani, D. L. Bigam, A. M. J. Shapiro, and N. M. Kneteman, “Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma,” Hepatology, vol. 51, no. 4, pp. 1237–1243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  130. T. Decaens, A. Luciani, E. Itti et al., “Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma,” Digestive and Liver Disease, vol. 44, no. 7, pp. 610–616, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. H. Huynh, K. H. Pierce Chow, K. C. Soo et al., “RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma,” Journal of Cellular and Molecular Medicine, vol. 13, no. 7, pp. 1371–1380, 2009. View at Publisher · View at Google Scholar · View at Scopus
  132. A. X. Zhu, M. Kudo, E. Assenat et al., “Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial,” JAMA, vol. 312, no. 1, pp. 57–67, 2014. View at Publisher · View at Google Scholar · View at Scopus
  133. D. F. Egan, M. G. H. Chun, M. Vamos et al., “Small molecule inhibition of the autophagy kinase ULK1 and identification of ULK1 substrates,” Molecular Cell, vol. 59, no. 2, pp. 285–297, 2015. View at Publisher · View at Google Scholar · View at Scopus
  134. H. E. Thomas, C. A. Mercer, L. S. Carnevalli et al., “mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma,” Science Translational Medicine, vol. 4, no. 139, pp. 139ra84–139ra19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  135. S. Shimizu, T. Takehara, H. Hikita et al., “Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma,” International Journal of Cancer, vol. 131, no. 3, pp. 548–557, 2012. View at Publisher · View at Google Scholar · View at Scopus
  136. J. Llovet, “Sorafenib in advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  137. A. L. Cheng, Y. K. Kang, Z. Chen et al., “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial,” The Lancet Oncology, vol. 10, no. 1, pp. 25–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. W.-T. Tai, C. W. Shiau, H. L. Chen et al., “Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells,” Cell Death & Disease, vol. 4, no. 2, pp. e485–e410, 2013. View at Publisher · View at Google Scholar · View at Scopus
  139. M. D. Bareford, M. A. Park, A. Yacoub et al., “Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells,” Cancer Research, vol. 71, no. 14, pp. 4955–4967, 2011. View at Publisher · View at Google Scholar · View at Scopus
  140. K.-F. Chen, H. L. Chen, W. T. Tai et al., “Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells,” The Journal of Pharmacology and Experimental Therapeutics, vol. 337, no. 1, pp. 155–161, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. M. A. Kowalik, A. Perra, G. M. Ledda-Columbano et al., “Induction of autophagy promotes the growth of early preneoplastic rat liver nodules,” Oncotarget, vol. 7, no. 5, pp. 5788–5799, 2016. View at Publisher · View at Google Scholar · View at Scopus
  142. Z. Chen, Y. Li, C. Zhang et al., “Downregulation of Beclin1 and impairment of autophagy in a small population of colorectal cancer,” Digestive Diseases and Sciences, vol. 58, no. 10, pp. 2887–2894, 2013. View at Publisher · View at Google Scholar · View at Scopus
  143. H.-Y. Zheng, X.-Y. Zhang, X.-F. Wang, and B.-C. Sun, “Autophagy enhances the aggressiveness of human colorectal cancer cells and their ability to adapt to apoptotic stimulus,” Cancer Biology & Medicine, vol. 9, no. 2, pp. 105–110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  144. G. F. Guo, W. Q. Jiang, B. Zhang et al., “Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer,” World Journal of Gastroenterology, vol. 17, no. 43, pp. 4779–4786, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. M. Yang, H. Zhao, L. Guo et al., “Autophagy-based survival prognosis in human colorectal carcinoma,” Oncotarget, vol. 6, no. 9, pp. 7084–7103, 2015. View at Publisher · View at Google Scholar
  146. C. Schonewolf, M. Mehta, D. Schiff et al., “Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation,” World Journal of Gastrointestinal Oncology, vol. 6, no. 3, pp. 74–82, 2014. View at Publisher · View at Google Scholar
  147. M.-Y. Zhang, W. F. Gou, S. Zhao et al., “Beclin 1 expression is closely linked to colorectal carcinogenesis and distant metastasis of colorectal carcinoma,” International Journal of Molecular Sciences, vol. 15, no. 8, pp. 14372–14385, 2014. View at Publisher · View at Google Scholar · View at Scopus
  148. K. Koneri, T. Goi, Y. Hirono, K. Katayama, and A. Yamaguchi, “Beclin 1 gene inhibits tumor growth in colon cancer cell lines,” Anticancer Research, vol. 27, pp. 1453–1458, 2007. View at Google Scholar
  149. C. H. Ahn, E. G. Jeong, J. W. Lee et al., “Expression of beclin-1, an autophagy-related protein, in gastric and colorectal cancers,” APMIS, vol. 115, no. 12, pp. 1344–1349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  150. Z. Yang, R. A. Ghoorun, X. Fan et al., “High expression of Beclin-1 predicts favorable prognosis for patients with colorectal cancer,” Clinics and Research in Hepatology and Gastroenterology, vol. 39, pp. 98–106, 2015. View at Publisher · View at Google Scholar · View at Scopus
  151. B.-X. Li, C. Y. Li, R. Q. Peng et al., “The expression of beclin 1 is associated with favorable prognosis in stage IIIB colon cancers,” Autophagy, vol. 5, no. 3, pp. 303–306, 2009. View at Publisher · View at Google Scholar · View at Scopus
  152. J. M. Park, S. Huang, T. T. Wu, N. R. Foster, and F. A. Sinicrope, “Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy,” Cancer Biology & Therapy, vol. 14, no. 2, pp. 100–107, 2013. View at Publisher · View at Google Scholar · View at Scopus
  153. J. H. Choi, Y. S. Cho, Y. H. Ko, S. U. Hong, J. H. Park, and M. A. Lee, “Absence of autophagy-related proteins expression is associated with poor prognosis in patients with colorectal adenocarcinoma,” Gastroenterology Research and Practice, vol. 2014, Article ID 179586, 10 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  154. C. H. An, M. S. Kim, N. J. Yoo, S. W. Park, and S. H. Lee, “Mutational and expressional analyses of ATG5, an autophagy-related gene, in gastrointestinal cancers,” Pathology, Research and Practice, vol. 207, no. 7, pp. 433–437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  155. Y. K. Jo, S. C. Kim, I. J. Park et al., “Increased expression of ATG10 in colorectal cancer is associated with lymphovascular invasion and lymph node metastasis,” PLoS One, vol. 7, no. 12, p. e52705, 2012. View at Publisher · View at Google Scholar · View at Scopus
  156. K. Sasaki, N. H. Tsuno, E. Sunami et al., “Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study,” Anticancer Drugs, vol. 23, no. 7, pp. 675–682, 2012. View at Publisher · View at Google Scholar · View at Scopus
  157. J. S. Carew, E. C. Medina, J. A. Esquivel II et al., “Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation,” Journal of Cellular and Molecular Medicine, vol. 14, no. 10, pp. 2448–2459, 2010. View at Publisher · View at Google Scholar · View at Scopus
  158. W.-X. Ding, H. M. Ni, W. Gao et al., “Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy,” Molecular Cancer Therapeutics, vol. 8, no. 7, pp. 2036–2045, 2009. View at Publisher · View at Google Scholar · View at Scopus
  159. G. Liu, F. Pei, F. Yang et al., “Role of autophagy and apoptosis in non-small-cell lung cancer,” International Journal of Molecular Sciences, vol. 18, no. 2, pp. 1–24, 2017. View at Publisher · View at Google Scholar · View at Scopus
  160. J. Y. Guo, G. Karsli-Uzunbas, R. Mathew et al., “Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis,” Genes & Development, vol. 27, no. 13, pp. 1447–1461, 2013. View at Publisher · View at Google Scholar · View at Scopus
  161. A. M. Strohecker, J. Y. Guo, G. Karsli-Uzunbas et al., “Autophagy sustains mitochondrial glutamine metabolism and growth of BRAFV206E-driven lung tumors,” Cancer Discovery, vol. 3, no. 11, pp. 1272–1285, 2013. View at Publisher · View at Google Scholar · View at Scopus
  162. V. Deretic, “Autophagy in immunity and cell-autonomous defense against intracellular microbes,” Immunological Reviews, vol. 240, no. 1, pp. 92–104, 2011. View at Publisher · View at Google Scholar · View at Scopus
  163. Y. Zou, Y. H. Ling, J. Sironi, E. L. Schwartz, R. Perez-Soler, and B. Piperdi, “The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib,” Journal of Thoracic Oncology, vol. 8, no. 6, pp. 693–702, 2013. View at Publisher · View at Google Scholar · View at Scopus
  164. J. T. Liu, W. C. Li, S. Gao et al., “Autophagy inhibition overcomes the antagonistic effect between gefitinib and cisplatin in epidermal growth factor receptor mutant non-small-cell lung cancer cells,” Clinical Lung Cancer, vol. 16, no. 5, pp. e55–e66, 2015. View at Publisher · View at Google Scholar · View at Scopus
  165. K. Chen and W. Shi, “Autophagy regulates resistance of non-small cell lung cancer cells to paclitaxel,” Tumor Biology, vol. 37, no. 8, pp. 10539–10544, 2016. View at Publisher · View at Google Scholar · View at Scopus
  166. S. Khushboo, R. W. Goehe, X. Di et al., “A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analogue, EB 1089,” Autophagy, vol. 10, no. 12, pp. 2346–2361, 2014. View at Publisher · View at Google Scholar · View at Scopus
  167. X. Zhang, J. Fan, S. Wang et al., “Targeting CD47 and autophagy elicited enhanced antitumor effects in non-small cell lung cancer,” Cancer Immunologic Research, vol. 5, no. 5, pp. 363–375, 2017. View at Publisher · View at Google Scholar · View at Scopus
  168. S. B. Goldberg, G. R. Oxnard, S. Digumarthy et al., “Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors,” The Oncologist, vol. 18, no. 11, pp. 1214–1220, 2013. View at Publisher · View at Google Scholar · View at Scopus
  169. H. Pan, L. Chen, Y. Xu et al., “Autophagy-associated immune responses and cancer immunotherapy,” Oncotarget, vol. 7, no. 16, pp. 21235–21246, 2016. View at Publisher · View at Google Scholar · View at Scopus